Cost-effective strategies for CAR-T cell therapy manufacturing
CAR-T cell therapy has revolutionized cancer treatment, with approvals for conditions like acute B-leukemia, large B cell lymphoma (LBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and multiple myeloma. However, its high costs limit accessibility. Key factors driving these costs include...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Molecular Therapy: Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950329925000499 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850150730377199616 |
|---|---|
| author | Luiza Abdo Leonardo Ribeiro Batista-Silva Martín Hernán Bonamino |
| author_facet | Luiza Abdo Leonardo Ribeiro Batista-Silva Martín Hernán Bonamino |
| author_sort | Luiza Abdo |
| collection | DOAJ |
| description | CAR-T cell therapy has revolutionized cancer treatment, with approvals for conditions like acute B-leukemia, large B cell lymphoma (LBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and multiple myeloma. However, its high costs limit accessibility. Key factors driving these costs include the need for personalized, autologous treatments, transportation to specialized facilities, reliance on viral vectors requiring advanced laboratories, and lengthy cell expansion processes. To address these challenges, alternative strategies aim to simplify and reduce production complexity. Non-viral vectors, such as Sleeping Beauty, piggyBac, and CRISPR, delivered via nanoparticles or electroporation, present promising solutions. These methods could streamline manufacturing, eliminate the need for viral vectors, and reduce associated costs. Furthermore, shortening cell expansion periods and optimizing protocols could significantly accelerate production. An emerging approach involves using genetically edited T cells from healthy donors to create universal CAR-T products capable of treating multiple patients. Finally, decentralized point-of-care (POC) manufacturing of CAR-T cells minimize logistical expenses, eliminating the need for complex infrastructure, and enabling localized production closer to patients. This innovative strategy holds potential for broadening access and reducing costs, representing a step toward democratizing CAR-T therapy. Combined, these advances could make this groundbreaking treatment more feasible for healthcare systems worldwide. |
| format | Article |
| id | doaj-art-1c175edb4a3748fe834e672e07644feb |
| institution | OA Journals |
| issn | 2950-3299 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncology |
| spelling | doaj-art-1c175edb4a3748fe834e672e07644feb2025-08-20T02:26:28ZengElsevierMolecular Therapy: Oncology2950-32992025-06-0133220098010.1016/j.omton.2025.200980Cost-effective strategies for CAR-T cell therapy manufacturingLuiza Abdo0Leonardo Ribeiro Batista-Silva1Martín Hernán Bonamino2Cell and Gene Therapy Program, Research Coordination, National Cancer Institute (INCA), Rio de Janeiro 20231-050, BrazilCell and Gene Therapy Program, Research Coordination, National Cancer Institute (INCA), Rio de Janeiro 20231-050, BrazilCell and Gene Therapy Program, Research Coordination, National Cancer Institute (INCA), Rio de Janeiro 20231-050, Brazil; Vice-Presidency of Research and Biological Collections (VPPCB), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil; Corresponding author: Martín Hernán Bonamino, Cell and Gene Therapy Program, Research Coordination, National Cancer Institute (INCA), Rio de Janeiro 20231-050, Brazil.CAR-T cell therapy has revolutionized cancer treatment, with approvals for conditions like acute B-leukemia, large B cell lymphoma (LBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and multiple myeloma. However, its high costs limit accessibility. Key factors driving these costs include the need for personalized, autologous treatments, transportation to specialized facilities, reliance on viral vectors requiring advanced laboratories, and lengthy cell expansion processes. To address these challenges, alternative strategies aim to simplify and reduce production complexity. Non-viral vectors, such as Sleeping Beauty, piggyBac, and CRISPR, delivered via nanoparticles or electroporation, present promising solutions. These methods could streamline manufacturing, eliminate the need for viral vectors, and reduce associated costs. Furthermore, shortening cell expansion periods and optimizing protocols could significantly accelerate production. An emerging approach involves using genetically edited T cells from healthy donors to create universal CAR-T products capable of treating multiple patients. Finally, decentralized point-of-care (POC) manufacturing of CAR-T cells minimize logistical expenses, eliminating the need for complex infrastructure, and enabling localized production closer to patients. This innovative strategy holds potential for broadening access and reducing costs, representing a step toward democratizing CAR-T therapy. Combined, these advances could make this groundbreaking treatment more feasible for healthcare systems worldwide.http://www.sciencedirect.com/science/article/pii/S2950329925000499MT: Regular IssueCAR-T cellcost-effectiveimmunotherapymanufacturingB cell tumor |
| spellingShingle | Luiza Abdo Leonardo Ribeiro Batista-Silva Martín Hernán Bonamino Cost-effective strategies for CAR-T cell therapy manufacturing Molecular Therapy: Oncology MT: Regular Issue CAR-T cell cost-effective immunotherapy manufacturing B cell tumor |
| title | Cost-effective strategies for CAR-T cell therapy manufacturing |
| title_full | Cost-effective strategies for CAR-T cell therapy manufacturing |
| title_fullStr | Cost-effective strategies for CAR-T cell therapy manufacturing |
| title_full_unstemmed | Cost-effective strategies for CAR-T cell therapy manufacturing |
| title_short | Cost-effective strategies for CAR-T cell therapy manufacturing |
| title_sort | cost effective strategies for car t cell therapy manufacturing |
| topic | MT: Regular Issue CAR-T cell cost-effective immunotherapy manufacturing B cell tumor |
| url | http://www.sciencedirect.com/science/article/pii/S2950329925000499 |
| work_keys_str_mv | AT luizaabdo costeffectivestrategiesforcartcelltherapymanufacturing AT leonardoribeirobatistasilva costeffectivestrategiesforcartcelltherapymanufacturing AT martinhernanbonamino costeffectivestrategiesforcartcelltherapymanufacturing |